Combivent is a drug owned by Boehringer Ingelheim Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 09, 2015. Details of Combivent's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5603918 | Aerosol composition of a salt of ipratropium and a salt of albuterol |
Jun, 2015
(9 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Combivent is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Combivent's family patents as well as insights into ongoing legal events on those patents.
Combivent's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Combivent's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 09, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Combivent Generic API suppliers:
Albuterol Sulfate; Ipratropium Bromide is the generic name for the brand Combivent. 9 different companies have already filed for the generic of Combivent, with Aiping Pharm Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Combivent's generic
Alternative Brands for Combivent
There are several other brand drugs using the same active ingredient (Albuterol Sulfate; Ipratropium Bromide) as Combivent. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Boehringer Ingelheim |
| |
| Norvium Bioscience |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Albuterol Sulfate; Ipratropium Bromide, Combivent's active ingredient. Check the complete list of approved generic manufacturers for Combivent
About Combivent
Combivent is a drug owned by Boehringer Ingelheim Pharmaceuticals Inc. Combivent uses Albuterol Sulfate; Ipratropium Bromide as an active ingredient. Combivent was launched by Boehringer Ingelheim in 1996.
Approval Date:
Combivent was approved by FDA for market use on 24 October, 1996.
Active Ingredient:
Combivent uses Albuterol Sulfate; Ipratropium Bromide as the active ingredient. Check out other Drugs and Companies using Albuterol Sulfate; Ipratropium Bromide ingredient
Dosage:
Combivent is available in aerosol, metered form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.09MG BASE/INH;0.018MG/INH | AEROSOL, METERED | Discontinued | INHALATION |